



Understanding the Evolving Immuno-Oncology Treatment Paradigm in Non-Small-Cell Lung Cancer

A Satellite CME Symposium

Join us for this dynamic, live stream, CME-certified webinar where experts will provide their insights on the optimal use of ICIs in the treatment of NSCLC via a series of patient cases, including discussion of the latest clinical data in early-stage and advanced-stage disease, clinical factors influencing response to these agents, and how emerging data may affect current treatment paradigms.

Tuesday, September 14, 2021

15:00 - 16:00 MT

To convert to your time zone, [click here](#).

[Webinar Registration](#)

Faculty Presenters

Julie Brahmer, MD, MSc

Bloomberg-Kimmel Institute for Cancer Immunology
Sidney Kimmel Comprehensive Cancer Center
Johns Hopkins Medicine
Baltimore, Maryland

Jarushka Naidoo, MB BCH BAO, MHS

Beaumont Hospital/RCSI University of Health Sciences
Dublin, Ireland
Johns Hopkins University
Baltimore, Maryland

Share with your colleagues!

Please share this event with your colleagues by forwarding this email. The program is designed to promote intradisciplinary and interdisciplinary competency on this topic.

Agenda

Welcome and Introduction

Overview of Immunotherapy in Nonmetastatic NSCLC – Jarushka Naidoo, MB BCH BAO, MHS

- Optimal use of immunotherapy in stage III NSCLC
- New directions: neoadjuvant and adjuvant immunotherapy in early-stage NSCLC

Evolving Role of Immunotherapy in Advanced or Metastatic NSCLC – Julie Brahmer, MD, MSc

- Current immunotherapy landscape in advanced NSCLC
- Immune resistance and sequencing of therapy
- Emerging biomarkers of response to ICI therapy in NSCLC

Immunotherapy in Advanced or Metastatic NSCLC: Special Populations – Jarushka Naidoo, MB BCH BAO, MHS

- Response to ICI-based therapy in patients with cachexia
- ICI-based therapy in patients with autoimmune disease and those who have undergone transplantation

Final Panel Discussion and Audience Question and Answer Session

This program was approved by the IASLC 2021 World Conference on Lung Cancer Program Committee as an independent activity held in conjunction with the IASLC 2021 World Conference on Lung Cancer. This program is not sponsored or endorsed by IASLC and is not part of the official IASLC accredited program.

Provided by Clinical Care Options, LLC.

Supported by educational grants from Bristol-Myers Squibb, Helsinn Healthcare SA, and Merck Sharp & Dohme Corp.
PRP4317


CLINICAL CARE OPTIONS®
ONCOLOGY



© 2021 Clinical Care Options, LLC. All rights reserved. 12001 Sunrise Valley Drive, Suite 300, Reston, VA 20191

To ensure you receive Clinical Care Options educational materials by email, please add cco@mail.clinicaloptions.com to your contacts or address book.

Click [here](#) to unsubscribe from or resubscribe to all communication.

[Not a member yet?](#) | [Too many emails? Manage subscription preferences](#)